Shopping Cart 0
Cart Subtotal
USD 0

Progenics Pharmaceuticals Inc (PGNX)-Financial and Strategic SWOT Analysis Review

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 125

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 250

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 375
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase

Details

Progenics Pharmaceuticals Inc (PGNX)-Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

Business description-A detailed description of the company operations and business divisions.

Corporate strategy-Analyst summarization of the company business strategy.

SWOT Analysis-A detailed analysis of the company strengths, weakness, opportunities and threats.

Company history-Progression of key events associated with the company.

Major products and services-A list of major products, services and brands of the company.

Key competitors-A list of key competitors to the company.

Key employees-A list of the key executives of the company.

Executive biographies-A brief summary of the executives' employment history.

Key operational heads-A list of personnel heading key departments/functions.

Important locations and subsidiaries-A list and contact details of key locations and subsidiaries of the company.

Key manufacturing facilities-A list of key manufacturing facilities of the company.

Detailed financial ratios for the past five years-The latest financial ratios derived from the annual financial statements published by the company with 5 years history.

Interim ratios for the last five interim periods-The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Progenics Pharmaceuticals Inc (Progenics) is a late-stage biopharmaceutical company that focuses on developing medicines and products for the treatment of cancer and related conditions. Its only commercial product, Relistor, is used for the treatment of opioid-induced constipation. The company pipeline comprises therapeutic agents that are designed to target cancer; PSMA-targeted imaging agents for prostate cancer that enable clinicians and patients to visualize and manage their disease; and a phase III candidate for the treatment of HIV. Progenics also offers bone scan index product EXINI Bone BSI tool and is approved for use in Europe, Japan and the US. The company markets Relistor, through a licensing agreement with Salix Pharmaceuticals outside the US except Japan. Progenics is headquartered in New York, the US.

Progenics Pharmaceuticals Inc Key Recent Developments

Jun 02,2017: Progenics Pharmaceuticals Announces the Presentation of Data From Two Automated Bone Scan Index Studies at the 2017 ASCO Annual Meeting

May 04,2017: Progenics Pharmaceuticals Announces First Quarter 2017 Financial Results and Business Update

Apr 20,2017: Progenics Pharmaceuticals Announces Presentations at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting

Mar 09,2017: Progenics Pharmaceuticals Announces Fourth Quarter and Full-Year 2016 Financial Results and Business Update

Dec 22,2016: Progenics Pharmaceuticals Announces Independent Committee Positive Recommendation for Continuation of Phase 3 Clinical Trial of SPECT/CT Imaging Agent 1404

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

The profile analyzes the company business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

The company core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.

Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Section 1-About the Company 6

Progenics Pharmaceuticals Inc-Key Facts 6

Progenics Pharmaceuticals Inc-Key Employees 7

Progenics Pharmaceuticals Inc-Key Employee Biographies 8

Progenics Pharmaceuticals Inc-Major Products and Services 9

Progenics Pharmaceuticals Inc-History 10

Progenics Pharmaceuticals Inc-Company Statement 13

Progenics Pharmaceuticals Inc-Locations And Subsidiaries 15

Head Office 15

Other Locations & Subsidiaries 15

Section 2-Company Analysis 16

Progenics Pharmaceuticals Inc-Business Description 16

Progenics Pharmaceuticals Inc-SWOT Analysis 17

SWOT Analysis-Overview 17

Progenics Pharmaceuticals Inc-Strengths 17

Progenics Pharmaceuticals Inc-Weaknesses 18

Progenics Pharmaceuticals Inc-Opportunities 19

Progenics Pharmaceuticals Inc-Threats 20

Progenics Pharmaceuticals Inc-Key Competitors 21

Section 3-Company Financial Ratios 22

Financial Ratios-Capital Market Ratios 22

Financial Ratios-Annual Ratios 23

Performance Chart 26

Financial Performance 26

Financial Ratios-Interim Ratios 27

Financial Ratios-Ratio Charts 28

Section 4-Company's Lifesciences Financial Deals and Alliances 29

Progenics Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 29

Progenics Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Type, 2011 to YTD 2017 30

Progenics Pharmaceuticals Inc, Recent Deals Summary 31

Section 5-Company's Recent Developments 32

Jun 02, 2017: Progenics Pharmaceuticals Announces the Presentation of Data From Two Automated Bone Scan Index Studies at the 2017 ASCO Annual Meeting 32

May 04, 2017: Progenics Pharmaceuticals Announces First Quarter 2017 Financial Results and Business Update 34

Apr 20, 2017: Progenics Pharmaceuticals Announces Presentations at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting 36

Mar 09, 2017: Progenics Pharmaceuticals Announces Fourth Quarter and Full-Year 2016 Financial Results and Business Update 37

Dec 22, 2016: Progenics Pharmaceuticals Announces Independent Committee's Positive Recommendation for Continuation of Phase 3 Clinical Trial of SPECT/CT Imaging Agent 1404 39

Dec 07, 2016: Progenics Pharmaceuticals Announces First Patient Dosed in Phase 2/3 Clinical Trial of PSMA-Targeted PET/CT Imaging Agent PyL 40

Nov 07, 2016: Progenics Pharmaceuticals Announces Third Quarter 2016 Financial Results and Business Update 41

Sep 07, 2016: Progenics Pharmaceuticals Announces Appointment of Bryce V. Tenbarge as Vice President of Commercial 43

Aug 04, 2016: Progenics Pharmaceuticals Announces Second Quarter 2016 Financial and Business Results 44

Jun 13, 2016: Progenics Pharmaceuticals Announces Presentations on its Prostate Cancer Imaging Programs at SNMMI 2016 45

Section 6-Appendix 46

Methodology 46

Ratio Definitions 46

About GlobalData 50

Contact Us 50

Disclaimer 50


List Of Figure

List of Figures

Progenics Pharmaceuticals Inc, Performance Chart (2012-2016) 26

Progenics Pharmaceuticals Inc, Ratio Charts 28

Progenics Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 29

Progenics Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 30


List Of Table

List of Tables

Progenics Pharmaceuticals Inc, Key Facts 6

Progenics Pharmaceuticals Inc, Key Employees 7

Progenics Pharmaceuticals Inc, Key Employee Biographies 8

Progenics Pharmaceuticals Inc, Major Products and Services 9

Progenics Pharmaceuticals Inc, History 10

Progenics Pharmaceuticals Inc, Subsidiaries 15

Progenics Pharmaceuticals Inc, Key Competitors 21

Progenics Pharmaceuticals Inc, Ratios based on current share price 22

Progenics Pharmaceuticals Inc, Annual Ratios 23

Progenics Pharmaceuticals Inc, Annual Ratios (Cont...1) 24

Progenics Pharmaceuticals Inc, Annual Ratios (Cont...2) 25

Progenics Pharmaceuticals Inc, Interim Ratios 27

Progenics Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 29

Progenics Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Type, 2011 to YTD 2017 30

Progenics Pharmaceuticals Inc, Recent Deals Summary 31

Currency Codes 46

Capital Market Ratios 46

Equity Ratios 47

Profitability Ratios 47

Cost Ratios 48

Liquidity Ratios 48

Leverage Ratios 49

Efficiency Ratios 49

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Progenics Pharmaceuticals Inc (PGNX)-Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

Business description-A detailed description of the company operations and business divisions.

Corporate strategy-Analyst summarization of the company business strategy.

SWOT Analysis-A detailed analysis of the company strengths, weakness, opportunities and threats.

Company history-Progression of key events associated with the company.

Major products and services-A list of major products, services and brands of the company.

Key competitors-A list of key competitors to the company.

Key employees-A list of the key executives of the company.

Executive biographies-A brief summary of the executives' employment history.

Key operational heads-A list of personnel heading key departments/functions.

Important locations and subsidiaries-A list and contact details of key locations and subsidiaries of the company.

Key manufacturing facilities-A list of key manufacturing facilities of the company.

Detailed financial ratios for the past five years-The latest financial ratios derived from the annual financial statements published by the company with 5 years history.

Interim ratios for the last five interim periods-The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Progenics Pharmaceuticals Inc (Progenics) is a late-stage biopharmaceutical company that focuses on developing medicines and products for the treatment of cancer and related conditions. Its only commercial product, Relistor, is used for the treatment of opioid-induced constipation. The company pipeline comprises therapeutic agents that are designed to target cancer; PSMA-targeted imaging agents for prostate cancer that enable clinicians and patients to visualize and manage their disease; and a phase III candidate for the treatment of HIV. Progenics also offers bone scan index product EXINI Bone BSI tool and is approved for use in Europe, Japan and the US. The company markets Relistor, through a licensing agreement with Salix Pharmaceuticals outside the US except Japan. Progenics is headquartered in New York, the US.

Progenics Pharmaceuticals Inc Key Recent Developments

Jun 02,2017: Progenics Pharmaceuticals Announces the Presentation of Data From Two Automated Bone Scan Index Studies at the 2017 ASCO Annual Meeting

May 04,2017: Progenics Pharmaceuticals Announces First Quarter 2017 Financial Results and Business Update

Apr 20,2017: Progenics Pharmaceuticals Announces Presentations at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting

Mar 09,2017: Progenics Pharmaceuticals Announces Fourth Quarter and Full-Year 2016 Financial Results and Business Update

Dec 22,2016: Progenics Pharmaceuticals Announces Independent Committee Positive Recommendation for Continuation of Phase 3 Clinical Trial of SPECT/CT Imaging Agent 1404

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

The profile analyzes the company business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

The company core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.

Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Section 1-About the Company 6

Progenics Pharmaceuticals Inc-Key Facts 6

Progenics Pharmaceuticals Inc-Key Employees 7

Progenics Pharmaceuticals Inc-Key Employee Biographies 8

Progenics Pharmaceuticals Inc-Major Products and Services 9

Progenics Pharmaceuticals Inc-History 10

Progenics Pharmaceuticals Inc-Company Statement 13

Progenics Pharmaceuticals Inc-Locations And Subsidiaries 15

Head Office 15

Other Locations & Subsidiaries 15

Section 2-Company Analysis 16

Progenics Pharmaceuticals Inc-Business Description 16

Progenics Pharmaceuticals Inc-SWOT Analysis 17

SWOT Analysis-Overview 17

Progenics Pharmaceuticals Inc-Strengths 17

Progenics Pharmaceuticals Inc-Weaknesses 18

Progenics Pharmaceuticals Inc-Opportunities 19

Progenics Pharmaceuticals Inc-Threats 20

Progenics Pharmaceuticals Inc-Key Competitors 21

Section 3-Company Financial Ratios 22

Financial Ratios-Capital Market Ratios 22

Financial Ratios-Annual Ratios 23

Performance Chart 26

Financial Performance 26

Financial Ratios-Interim Ratios 27

Financial Ratios-Ratio Charts 28

Section 4-Company's Lifesciences Financial Deals and Alliances 29

Progenics Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 29

Progenics Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Type, 2011 to YTD 2017 30

Progenics Pharmaceuticals Inc, Recent Deals Summary 31

Section 5-Company's Recent Developments 32

Jun 02, 2017: Progenics Pharmaceuticals Announces the Presentation of Data From Two Automated Bone Scan Index Studies at the 2017 ASCO Annual Meeting 32

May 04, 2017: Progenics Pharmaceuticals Announces First Quarter 2017 Financial Results and Business Update 34

Apr 20, 2017: Progenics Pharmaceuticals Announces Presentations at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting 36

Mar 09, 2017: Progenics Pharmaceuticals Announces Fourth Quarter and Full-Year 2016 Financial Results and Business Update 37

Dec 22, 2016: Progenics Pharmaceuticals Announces Independent Committee's Positive Recommendation for Continuation of Phase 3 Clinical Trial of SPECT/CT Imaging Agent 1404 39

Dec 07, 2016: Progenics Pharmaceuticals Announces First Patient Dosed in Phase 2/3 Clinical Trial of PSMA-Targeted PET/CT Imaging Agent PyL 40

Nov 07, 2016: Progenics Pharmaceuticals Announces Third Quarter 2016 Financial Results and Business Update 41

Sep 07, 2016: Progenics Pharmaceuticals Announces Appointment of Bryce V. Tenbarge as Vice President of Commercial 43

Aug 04, 2016: Progenics Pharmaceuticals Announces Second Quarter 2016 Financial and Business Results 44

Jun 13, 2016: Progenics Pharmaceuticals Announces Presentations on its Prostate Cancer Imaging Programs at SNMMI 2016 45

Section 6-Appendix 46

Methodology 46

Ratio Definitions 46

About GlobalData 50

Contact Us 50

Disclaimer 50


List Of Figure

List of Figures

Progenics Pharmaceuticals Inc, Performance Chart (2012-2016) 26

Progenics Pharmaceuticals Inc, Ratio Charts 28

Progenics Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 29

Progenics Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 30


List Of Table

List of Tables

Progenics Pharmaceuticals Inc, Key Facts 6

Progenics Pharmaceuticals Inc, Key Employees 7

Progenics Pharmaceuticals Inc, Key Employee Biographies 8

Progenics Pharmaceuticals Inc, Major Products and Services 9

Progenics Pharmaceuticals Inc, History 10

Progenics Pharmaceuticals Inc, Subsidiaries 15

Progenics Pharmaceuticals Inc, Key Competitors 21

Progenics Pharmaceuticals Inc, Ratios based on current share price 22

Progenics Pharmaceuticals Inc, Annual Ratios 23

Progenics Pharmaceuticals Inc, Annual Ratios (Cont...1) 24

Progenics Pharmaceuticals Inc, Annual Ratios (Cont...2) 25

Progenics Pharmaceuticals Inc, Interim Ratios 27

Progenics Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 29

Progenics Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Type, 2011 to YTD 2017 30

Progenics Pharmaceuticals Inc, Recent Deals Summary 31

Currency Codes 46

Capital Market Ratios 46

Equity Ratios 47

Profitability Ratios 47

Cost Ratios 48

Liquidity Ratios 48

Leverage Ratios 49

Efficiency Ratios 49

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com